AI Takeaway
IDEXX Laboratories delivered strong FY2025 results with revenue growing 10.4% to $4.30B, operating income surging 20.5% to $1.36B, and net income rising 19.3% to $1.06B, driven by expanding margins and robust cash generation that funded $1.22B in share buybacks.
Revenue
$4.3B
++10.42% YoY
EPS (Basic)
$13.17
++22.28% YoY
Gross Margin
61.8%
++0.76% YoY
Operating Income
$1.36B
++20.53% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-K filing
IDEXX grew total revenue by 10.4% year-over-year to $4.30B in FY2025 (from $3.90B in FY2024), reflecting continued demand for companion animal diagnostics and veterinary software solutions. This consistent double-digit growth underscores the company's strong market position in the veterinary diagnostics industry.
Source: Source: 10-K Income Statement (XBRL Financial Data)
Gross margin improved modestly to 61.8% (from 61.0%), while operating margin expanded meaningfully by 265 basis points to 31.6% (from 29.0%), indicating strong operating leverage as revenue growth outpaced cost growth. Cost of revenue grew only 8.3% versus revenue growth of 10.4%, demonstrating disciplined cost management.
Source: Source: 10-K Income Statement & Key Ratios (XBRL Financial Data)
Research and development expenses increased 14.3% to $251.2M in FY2025 (from $219.8M), growing faster than revenue, signaling continued investment in innovation and new product development to sustain long-term competitive advantages in veterinary diagnostics.
Source: Source: 10-K Income Statement (XBRL Financial Data)
2 more insights available
Upgrade to unlockIDEXX's revenue is heavily concentrated in the companion animal diagnostics market, making it vulnerable to any slowdown in veterinary visits, pet ownership trends, or changes in pet healthcare spending. An economic downturn that reduces discretionary pet care spending could materially impact revenue growth. The company's high valuation multiples amplify the downside risk from any deceleration in this niche market.
Source: Source: 10-K Financial Data (XBRL)
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $3.08 versus the $2.99 analyst consensus — a +3.1% beat for FY2025.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $4.3B | $3.9B | +10.42% |
Cost of Revenue | $1.64B | $1.52B | +8.27% |
Gross Profit | $2.66B | $2.38B | +11.80% |
Operating Income | $1.36B | $1.13B | +20.53% |
Net Income | $1.06B | $887.87M | +19.33% |
EPS (Basic) | $13.17 | $10.77 | +22.28% |
EPS (Diluted) | $13.08 | $10.67 | +22.59% |
R&D Expense | $251.21M | $219.79M | +14.29% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $3.35B | $3.29B | +1.74% |
Current Assets | $1.41B | $1.4B | +1.00% |
Total Liabilities | $1.75B | $1.7B | +2.78% |
Current Liabilities | $1.15B | $1.07B | +7.58% |
Stockholders' Equity | $1.61B | $1.6B | +0.63% |
Cash & Equivalents | $180.07M | $288.27M | -37.53% |
Long-Term Debt | $450M | $617.8M | -27.16% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.18B | $929M | +27.21% |
Investing Cash Flow | $-136.24M | $-207.06M | +34.20% |
Financing Cash Flow | $-1.16B | $-878.07M | -32.67% |
Share Buybacks | $1.22B | $837.03M | +45.39% |
D&A | $145.18M | $129.94M | +11.73% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 61.8% | 61.0% | +0.76% |
Operating Margin | 31.6% | 29.0% | +2.65% |
Net Margin | 24.6% | — | — |
ROE | 66.0% | — | — |
ROA | 31.6% | — | — |
Current Ratio | $1.231 | — | — |
Debt to Equity | $1.087 | — | — |
Other companies in Health Care Equipment
IDEXX delivered strong FY2025 results with revenue of $4.30B, up 10.4% year-over-year, and net income of $1.06B, up 19.3%. Operating margin expanded to 31.6% from 29.0%, and diluted EPS grew 22.6% to $13.08, reflecting both earnings growth and the benefit of share buybacks.
IDEXX's 10.4% revenue growth to $4.30B in FY2025 was driven by continued demand for companion animal diagnostic products and services, with gross profit growing even faster at 11.8% to $2.66B. The company also increased R&D spending by 14.3% to $251.2M to support future product innovation and growth.
IDEXX repurchased $1.22B of its own shares in FY2025, a 45.4% increase from $837M in the prior year. This aggressive buyback program was funded by strong operating cash flow of $1.18B and contributed to a 22.6% increase in diluted EPS, as the share count was meaningfully reduced.
Key risks include IDEXX's concentrated exposure to the companion animal veterinary market, which is sensitive to economic downturns and changes in pet healthcare spending. Additionally, the company's cash position declined 37.5% to $180M amid aggressive buybacks, and current liabilities grew faster than current assets, compressing the current ratio to 1.23x and tightening short-term liquidity.
IDEXX's financial health is strong overall, with a 61.8% gross margin, 31.6% operating margin, and ROA of 31.6% reflecting a highly profitable and capital-efficient business. However, the current ratio of 1.23x and a debt-to-equity ratio of 1.09x, combined with a declining cash balance of $180M, suggest moderate leverage and limited liquidity headroom that investors should monitor.